|
End-of-day quote
Bratislava S.E.
2026-08-25
|
5-day change | 1st Jan Change | ||
| 17.20 EUR | +1.18% |
|
+1.18% | +72.00% |
| 04-28 | Biotika a.s. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 25-09-25 | Biotika a.s. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 12.04M 14.03M 11.27M 10.32M 19.44M 1.34B 19.5M 133M 52.18M 675M 52.66M 51.52M 2.23B | P/E 2024 |
-4.39x | P/E 2025 | -5.89x |
|---|---|---|---|---|---|
| Enterprise Value | 8.33M 9.7M 7.79M 7.14M 13.45M 926M 13.48M 92.3M 36.08M 467M 36.41M 35.63M 1.55B | EV / Sales 2024 |
0.55x | EV / Sales 2025 | 0.18x |
| Free-Float |
42.84% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.18% | ||
| 1 week | +1.18% | ||
| Current month | -14.00% | ||
| 1 month | -15.69% | ||
| 3 months | +62.26% | ||
| 6 months | +56.36% | ||
| Current year | +72.00% |
| 1 week | 17.2 |  | 17.2 |
| 1 month | 17 | | 20 |
| Current year | 9 | | 23 |
| 1 year | 7 | | 23 |
| 3 years | 7 | | 25 |
| 5 years | 7 | | 42 |
| 10 years | 7 | | 50.02 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marek Tarda
CEO | Chief Executive Officer | - | - |
P. Zila
CTO | Chief Tech/Sci/R&D Officer | - | - |
Milan Zemko
CIO | Chief Investment Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Dasa Bokorova
CHM | Chairman | - | - |
Filip Novak
BRD | Director/Board Member | - | - |
Anna Valachova
BRD | Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.18% | +1.18% | +115.00% | -21.82% | 14.03M | |
| +0.73% | +0.70% | +19.56% | +71.29% | 47.78B | |
| +0.33% | +1.37% | +54.82% | +122.59% | 40.3B | |
| +3.41% | +7.67% | +20.38% | +87.48% | 12.03B | |
| +1.23% | -0.14% | -10.12% | +15.55% | 11.88B | |
| +0.19% | 0.00% | +30.98% | +150.00% | 9.24B | |
| +0.45% | +3.73% | +25.09% | +46.01% | 7.83B | |
| -0.04% | -0.20% | +52.20% | -12.02% | 7.34B | |
| +0.89% | +9.50% | +26.11% | +220.67% | 7.21B | |
| +0.95% | -8.22% | -39.88% | +16.67% | 5.28B | |
| Average | +0.93% | -0.36% | +29.42% | +69.64% | 14.89B | |
| Weighted average by Cap. | +0.81% | +1.06% | +27.63% | +86.77% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 17.24M 20.08M 16.14M 14.78M 27.84M 1.92B 27.92M 191M 74.71M 967M 75.4M 73.77M 3.2B | 18.15M 21.15M 17M 15.56M 29.32M 2.02B 29.4M 201M 78.67M 1.02B 79.4M 77.68M 3.37B |
| Net income | -2.39M -2.78M -2.24M -2.05M -3.86M -266M -3.87M -26.5M -10.36M -134M -10.45M -10.23M -444M | -1.19M -1.39M -1.11M -1.02M -1.92M -132M -1.93M -13.18M -5.15M -66.67M -5.2M -5.09M -221M |
| Net Debt | -1.07M -1.24M -997K -913K -1.72M -118M -1.72M -11.81M -4.62M -59.72M -4.66M -4.56M -198M | -3.71M -4.33M -3.48M -3.18M -6M -413M -6.02M -41.18M -16.1M -208M -16.25M -15.9M -689M |
Employees
165
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- 1BSL01AE Stock
Select your edition
All financial news and data tailored to specific country editions
